Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug teclistamab tested in patients with Hard-to-Treat myeloma

NCT ID NCT06062537

Disease control Sponsor: Intergroupe Francophone du Myelome Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 200 adults with multiple myeloma whose cancer has returned or stopped responding to treatment. They are receiving teclistamab, a drug that helps the immune system find and destroy myeloma cells. Researchers are measuring how many patients respond to the drug and monitoring side effects in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
teclistamab (a drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this study could confirm that teclistamab works well and is safe for patients with multiple myeloma who have not responded to other treatments.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Teclistamab can cause serious side effects like infections or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Sep 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

French adult patient relapsed and refractory multiple myeloma receving teclistamab

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (≥18 years) with multiple myeloma who will receive at least one dose of teclistamab (first dose of the step-up dose) Exclusion Criteria: * Patients alive at the start of the study who did not receive study information or who objected to the collection of data * Patients who received teclistamab as part of an interventional clinical trial * Patients who are initiating teclistamab as part of a current interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • CH Bretagne Atlantique

    Vannes, France

  • CH Dunkerque

    Dunkirk, France

  • CH Perpignan

    Perpignan, France

  • CH d'ANNECY

    Annecy, France

  • CH de METZ

    Metz, France

  • CHU Amiens Picardie

    Amiens, France

  • CHU Bordeaux

    Bordeaux, 31400, France

  • CHU CAEN

    Caen, France

  • CHU Clermont-Ferrand Site Estaing

    Clermont-Ferrand, France

  • CHU Henri Mondor

    Créteil, France

  • CHU Saint-Eloi - CHU de Montpellier

    Montpellier, France

  • CHU Toulouse

    Toulouse, France

  • CHU de Besançon

    Besançon, France

  • CHU de Lille

    Lille, France

  • CHU de Nice

    Nice, France

  • CHU de Tours

    Tours, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre hospitalier Métropole de Savoie

    Chambéry, France

  • Centre hospitalier d'Argenteuil

    Argenteuil, France

  • Centre hospitalier de Brive-la-Gaillarde

    Brive-la-Gaillarde, France

  • Chu Dijon

    Dijon, France

  • Chu de Nantes

    Nantes, France

  • Chu de Rennes

    Rennes, France

  • Groupe hospitalier Bretagne Sud

    Lorient, France

  • Hopital Necker

    Paris, France

  • Hopital Novo

    Pontoise, France

  • Hopital de Hautepierre

    Strasbourg, France

  • Hopital de la cote Basque

    Bayonne, France

  • Hopital saint louis

    Paris, France

  • Institut Paoli Calmette

    Marseille, France

  • Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne

    Saint-Priest-en-Jarez, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.